Last update 10 Nov 2024
HBW-3220
Last update 10 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms HBW 3220, HBW-3-20, HBW-3220 + [1] |
Target |
Mechanism BTK C481S inhibitors(Bruton Tyrosine Kinase C481S inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with HBW-3220A multicenter phase ?/? study Evaluating the safety, tolerability, efficacy and pharmacokinetics of HBW-3220 capsules in Chinese patients with mature B cell lymphoma
HBW-3220胶囊在中国成熟B细胞淋巴瘤患者中的安全性、耐受性、有效性和药代动力学的多中心Ⅰ/II期临床研究
[Translation] A multicenter phase I/II clinical study on the safety, tolerability, efficacy and pharmacokinetics of HBW-3220 capsules in Chinese patients with mature B-cell lymphoma
100 Clinical Results associated with HBW-3220
Login to view more data
100 Translational Medicine associated with HBW-3220
Login to view more data
100 Patents (Medical) associated with HBW-3220
Login to view more data
100 Deals associated with HBW-3220
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Phase 2 | CN | 09 May 2022 | |
| Autoimmune Diseases | Phase 1 | CN | - | |
| Glomerulonephritis | IND Approval | CN | 30 Jun 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
AACR2024 Manual  | Phase 1 | 28 | ojcfrixhfa(iftqjmldyh) = Adverse events (AEs), similar to other BTKis, were mostly Grade 1 or 2, including fever (38%), diarrhea (35%), headache (19%), anemia (42%), infectious pneumonia (23%), decreased neutrophils (42%), decreased platelet count (27%), increased alanine aminotransferase (23%), etc. plqbiqlrvg (sbuwzkampy ) View more | Positive | 05 Apr 2024 | ||
CTR20221130 (ASCO2023) Manual | Phase 1 | 11 | qvenynygnm(aqoazvbivg) = hoqckyadze auyewypmen (mptdjdxfbx ) View more | Positive | 31 May 2023 | ||
Not Applicable | - | - | fpvlymxhzu(nivxebaizv) = ujmrkggpgo jhflvwjeux (uslfvxoylz ) View more | - | 09 Jun 2021 | ||
fpvlymxhzu(nivxebaizv) = wglgeifrqt jhflvwjeux (uslfvxoylz ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free